What is the equity of InflaRx this year?
InflaRx has equity of 102.58 M EUR this year.
InflaRx Equity 2024
InflaRx Equity
102.58 M EUR
Ticker
IFRX
ISIN
NL0012661870
WKN
A2H7A5
In 2024, InflaRx's equity was 102.58 M EUR, a 16.17% increase from the 88.3 M EUR equity in the previous year.
InflaRx Aktienanalyse
What does InflaRx do?
Inflarx NV is a biotech company that was founded in 2007 and is headquartered in Jena, Germany. The company's goal is to develop innovative therapies for patients suffering from severe inflammatory diseases. Inflarx focuses on the active ingredient IFX-1, which can be used for various diseases. The company collaborates closely with partners from the industry and science to advance the development of new therapies. The history of Inflarx began in 2007 when Dr. Niels C. Riedemann, the co-founder of the company, discovered IFX-1. IFX-1 is an antibody that can selectively inhibit inflammatory processes in the body. Riedemann recognized the potential of IFX-1 to form a new class of therapeutics and subsequently founded Inflarx. Initially, Inflarx focused on the development of IFX-1 for the treatment of lung inflammation. However, the company later recognized the potential of IFX-1 for other diseases, including autoimmune diseases and rare diseases. Today, the company specializes in the development and marketing of therapies for the treatment of inflammatory diseases in adults. Inflarx's business model is based on the development and marketing of therapies using IFX-1. The company collaborates closely with partners from the pharmaceutical industry and science to develop new therapies. Inflarx has filed several patents for IFX-1 and has exclusive rights to its use in certain diseases. The company operates in several divisions. The "Lung Inflammatory Diseases" division focuses on the development of therapies for the treatment of lung inflammation. The "Autoimmune Diseases" division includes the development of therapies for the treatment of autoimmune diseases such as rheumatoid arthritis and Crohn's disease. The "Rare Diseases" division focuses on the development of therapies for the treatment of rare diseases where IFX-1 can be utilized. Currently, Inflarx does not offer any products on the market. However, the company is working on the development of therapies for the treatment of inflammatory diseases in adults. IFX-1 is currently in various stages of clinical development and is being tested for different indications. Inflarx has received promising data from clinical trials and plans to bring IFX-1 to the market in the future. In summary, Inflarx NV is a biotech company specializing in the development of therapies for the treatment of inflammatory diseases. The company discovered IFX-1 as an active ingredient and continues to develop its products based on it. Inflarx collaborates closely with partners from the pharmaceutical industry and science to develop new therapies and specializes in various divisions. Although Inflarx currently does not have any products on the market, the company has received promising data from clinical trials and plans to enter the market with IFX-1 in the future. InflaRx ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing InflaRx's Equity
InflaRx's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding InflaRx's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating InflaRx's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
InflaRx's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in InflaRx’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about InflaRx stock
What was the equity of InflaRx compared to the previous year?
The equity of InflaRx has increased/decreased by 16.17% increased compared to the previous year.
What impact does a high equity have on investors of InflaRx?
A high equity is advantageous for investors of InflaRx as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of InflaRx?
A low equity can be a risk for investors of InflaRx, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of InflaRx affect the company?
An increase in equity of InflaRx can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of InflaRx affect the company?
A reduction in equity of InflaRx can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of InflaRx?
Some factors that can affect the equity of InflaRx include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of InflaRx so important for investors?
The equity of InflaRx is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can InflaRx take to change the equity?
To change equity, InflaRx can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does InflaRx pay?
Over the past 12 months, InflaRx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, InflaRx is expected to pay a dividend of 0 EUR.
What is the dividend yield of InflaRx?
The current dividend yield of InflaRx is .
When does InflaRx pay dividends?
InflaRx pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of InflaRx?
InflaRx paid dividends every year for the past 0 years.
What is the dividend of InflaRx?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is InflaRx located?
InflaRx is assigned to the 'Health' sector.
Wann musste ich die Aktien von InflaRx kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of InflaRx from 10/30/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/30/2024.
When did InflaRx pay the last dividend?
The last dividend was paid out on 10/30/2024.
What was the dividend of InflaRx in the year 2023?
In the year 2023, InflaRx distributed 0 EUR as dividends.
In which currency does InflaRx pay out the dividend?
The dividends of InflaRx are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The InflaRx stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von InflaRx
Our stock analysis for InflaRx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of InflaRx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
